Q-omics provides the consensus-scored RPS20P31 profile across patient tissues and cancer cell-line models. RPS20P31 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, RPS20P31 is differentially expressed in 7, with the highest sampling consensus in LUSC. Additionally, RPS20P31 RNA expression shows 7,556 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight COAD, LUSC, and LAML as cancer lineages where RPS20P31 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS20P31 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS20P31 survival associations across molecular data types. RPS20P31 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS20P31 RNA expression–survival associations across cancer types. High RPS20P31 expression shows unfavorable associations in COAD, BRCA, ACC, UVM and KIRP, but favorable associations in UCS. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for RPS20P31 RNA expression.
This table summarizes RPS20P31 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPS20P31. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS20P31 shows lower tumor expression in LUSC, BRCA and LUAD and higher tumor expression in COAD, KICH and HNSC. The LUSC box plot shows higher RPS20P31 RNA expression in normal versus tumor tissue (log2 FC = −0.185, t-test p < 0.001).
This table shows molecular features associated with RPS20P31 in patient tissues and cancer cell lines. In patient samples, RPS20P31 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
